¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glycogen storage disease type III"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
The Root of Ambulatory Care(¿Ü·¡ Áø·á Áöħ¼­), ÀÌÁø¿ì, ±ºÀÚÃâÆÇ»ç Á¦¸ñ °Ë»ö : 5 ÆäÀÌÁö: 1 Ã¥ ³»¿ë ³»ºÎ °Ë»öÇϱâ
  • 2 Àå - Endocrine disease (³»ºÐºñ Áúȯ)
    ..Diabetes mellitus Type II¦¢42 ..Goiter-Thyroid nodule¦¢50 ..Hyperthyroidism¦¢54 ..Hypothyroidism¦¢62 ..Obesity¦¢68 ..Osteoporosis¦¢74 ** Endocrine diseases...
     
  • Diabetes Mellitus Type II (´ç´¢º´ Á¦IIÇü)
    Classification ¢º Type I diabetes : ¥â-cell destruction, - Immune mediated - Idiopathic ¢º Type II diabetes : insulin resistance with relative insulin deficiency to a predominantly secretary defect with insulin resistance ¢º Gestational diabetes...
     
  • Chronic Liver Disease (¸¸¼º °£¿°)
    ..The term chronic liver disease¡¯encompasses a large number of conditions having different etiologies and existing on a continuum between hepatitis infection and cirrhosis. ..CLDÀÇ ÁÖ¿ä¿øÀÎ - Viral infections (Hepatitis B, Hepatitis C) - Toxins a...
     
  • GERD (gastroesophageal reflux disease - À§½Äµµ¿ª·ùº´)
    ..GERD´Â À§³»¿ë¹°ÀÌ ½Äµµ·Î ¿ª·ùÇÔÀ¸·Î½á ¹ß»ýÇÏ´Â ÁúȯÀ¸·Î ºñ¹Ì¶õ¼º ¿ª ·ùÁúȯ (60%), ½Äµµ¿°(35%), ¶Ç´Â ÇÕº´ÁõÀÌ ÀÖ´Â ½Äµµ¿° (5%) µîÀ» À¯¹ßÇÑ´Ù. ..Pathophysiology - Àϰú¼ºÀÇ ÇϺνĵµ°ý¾à±ÙÀÇ ÀÌ¿Ï (transient ¡é LES tone) - ³·Àº ÇϺνĵµ°ý¾à±Ù¾Ð (sustained ¡éLES tone) - ÇØºÎÇÐÀû ±¸Á¶ÀÇ ¼Õ»óÀ¸·Î ¹ß»ýÇÑ ½Äµµ¿­°øÅ»Àå µî Typical 1. Heartburn : ...
     
  • Hepatitis type B (BÇü °£¿°)
    ..ÀüÆÄ°æ·Î 1) ÁÖ·Î ºñ°æ±¸ÀûÀÎ °æ·Î³ª Ä£¹ÐÇÑ °³ÀÎÀûÀÎ Á¢ÃË 2) ¸ðü·ÎºÎÅÍÀÇ ¼öÁ÷ °¨¿° 3) °¡Á·³» °¨¿° ¢º °íÀ§Ç豺 (1) high endemic area¿¡¼­ Ãâ»ýÇÑ »ç¶÷ (2) µ¿¼º¾Ö ³²ÀÚ (3) °æÇÇÀû ¾à¹° »ç¿ëÀÚ (4) Ç÷¾× Åõ¼®ÀÚ (5) HIV °¨¿°ÀÚ (6) ÀÓ»êºÎ (7) BÇü °£¿° ȯÀÚÀÇ °¡Á·, µ¿°ÅÀÎ, ¼ºÀû Á¢ÃËÀÚ ..Chronic hepatitis B - HBsAg(+) > 6 months - S...
     
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • factor III
    Á¦3ÀÎÀÚ
  • copper storage disease
    ±¸¸®ÃàÀûº´
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • cholesteryl ester storage disease
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅ׸£ÃàÀûº´
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûº´, ´ç¿øÃàÀûº´
  • iron-storage disease
    öÃàÀûÁúȯ
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lysosomal storage disease
    ¿ëÇØ¼ÒüÃàÀûº´, ¸®¼ÒÁ»ÃàÀûº´
  • phytanic acid storage disease
    ÇÇź»êÃàÀûº´
  • storage
    1. ÃàÀû 2. º¸Á¸, ÀúÀå 3. ±â¾ïÀåÄ¡
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • copper storage disease
    ±¸¸®ÀúÀ庴
  • cystine storage disease
    ½Ã½ºÆ¾ÃàÀûº´
  • glucose storage disease
    ´çÃàÀûº´
  • glycogen storage disease
    ´ç¿øÃàÀûº´
  • lipid storage disease
    ÁöÁúÃàÀûº´
  • lysosomal storage disease
    ¸®¼Ò¼ØÃàÀûº´, ¿ëÇØ¼ÒüÃàÀûº´
  • neuronal storage disease
    ½Å°æ¼¼Æ÷ÀúÀ庴
  • stock organism storage
    º¸Á¸¼¼±ÕÀúÀå
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage disease
    ÃàÀûº´
  • storage iron
    ˜ˌ̦
  • storage-type
    ÃàÀûÇü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Dorfman-Chanarin syndrome = neutral lipid storage disease
    Áß¼ºÁö¹æÃàÀûÁõ
  • glucose storage disease
    ´çÃàÀûÁúȯ.
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • image storage
    ¿µ»óÀúÀå<--ÃàÀû
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • DSM-III
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ
  • DSM-III-R
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ °³Á¤ÆÇ
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • oculomotor nerve (iii)
    ´«µ¹¸²½Å°æ
  • os metacarpale III ³ª
    ¼Â°¼Õ¹Ù´Ú<Áß¼ö>»À, Á¦»ïÁß¼ö°ñ(ð¯ß²ñéâ¢Íé).
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • third arch (iii)
    ¼Â°±ÁÀÌ
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Oculomotor nerve (III)
    ´«µ¹¸²½Å°æ
    [¿¾ ¿ë¾î] µ¿¾È½Å°æ
  • Third arch (III)
    ¼Â°±ÁÀÌ
    [¿¾ ¿ë¾î] Á¦»ï±Ã
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • DNA polymerase III
    DNA Æú¸®¸Ó·¹À̽º III
  • enzyme III
    È¿¼Ò(ý£áÈ) III
  • exonuclease III
    ¿¢¼Ò´©Å¬¸®¿¡À̽º III
  • HTLV-III
    (å²) human T cell lymphostrophic virus
  • ribonuclease III
    ¶óÀ̺¸´ºÅ¬¸®¿¡À̽º III
  • glycogen storage disease
    ±Û¶óÀÌÄÚÀü ÀúÀå Áúȯ(îÍíúòðü´)
  • lipid storage disease
    ÁöÁúÀúÀåÁúȯ(ò·òõîÍíúòðü´)
  • lysosomal storage disease
    ¶óÀ̼ÒÁ»³»(Ò®) ÀúÀåÁúȯ(îÍíúòðü´)
  • mucopolysaccharide storage disease
    ¹ÂÄÚ´Ù´çÁú(ÒýÓØòõ)ÀúÀåÁúȯ(îÍíúòðü´)
  • phytanic acid storage syndrome
    ÇÇź»ê(ß«) ÃàÀû ÁõÈıº(õëîÝñøý¦ÏØ)
  • storage mRNA
    ÀúÀå(îÍíú) mRNA
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • glycogen storage disease
    ±Û¸®ÄÚ°Õ ÃàÀûÁúȯ
  • long-term storage
    Àå±âÀúÀå(ÀåÄ¡)
  • short-term storage
    ´Ü±âÀúÀå(ÀåÄ¡)
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
  • storage disease
    ÃàÀûÁõ
  • storage oscilloscope
    ÀúÀå½Ä¿À½Ç·Î½ºÄÚÇÁ
  • storage tube
    ÀúÀå°ü
  • virtual storage
    °¡»ó±â¾ïÀåÄ¡
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
AT III angiotensin III; antithrombin III
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
ML I, II, III, IV mucolipidosis I, II, III, IV
AI, AII, AIII angiotensin I, II, III
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GSD III Glycogen storage disease type III
A III Angiotensin III
ANG III Angiotensin III
AP III Antipyrylazo III
AP III Atriopeptin III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lipid storage
    Áö¹æ ÀúÀå
    Áö¹æ ¼¼Æ÷°¡ ´ã´çÇÏ´Â ±â´ÉÀ¸·Î ü³»¿¡ Èí¼öµÈ Áö¹æÀº ų·Î¹ÌÅ©·ÐÀÇ ÇüÅ·Πü¼øÈ¯À» ÇÏ°Ô µÇ¸ç, Áö¹æ Á¶Á÷ÀÇ ¸ð¼¼Ç÷°ü¿¡ À̸£¸é ³»ÇÇ ¼¼Æ÷ÀÇ ´çÁöÁú ¸®ÆÄ¾ÆÁ¦ÀÇ ÀÛ¿ëÀ¸·Î À¯¸® Áö¹æ»ê°ú ´Ü´ç·ù·Î ºÐÇØµÇ¾î Áö¹æ ¼¼Æ÷¿¡ ÀÇÇØ ´Ü¼ø È®»êÀ¸·Î ¼·ÃëµÈ´Ù. ÀÌ Áö¹æ»êÀº Áö¹æ ÇÕ¼º È¿¼Ò¿¡ ÀÇÇÏ¿© Áß¼º Áö¹æÀ¸·Î ÇÕ¼ºµÇ¸ç Áö¹æ ºÐÇØ È¿¼Ò¸¦ ¾ïÁ¦ÇÏ¿© Áö¹æÀ» ÃàÀû½ÃŲ´Ù.
  • neuronal storage disease
    ½Å°æ ÃàÀûÁõ
  • storage
    ÃàÀû, º¸Á¸, ÀúÀå
    Ä¡°ú º¸Ã¶ ¿µ¿ª¿¡¼­´Â °¡Ã¶ ÀÇÄ¡ÀÇ ºÐ½Ç, ÆÄ¼Õ, ¹× º¯ÇüÀ» ¿¹¹æÇϱâ À§ÇÏ¿© ¾ÈÀüÇÑ Àå¼ÒÀÎ ¹° ¼Ó¿¡ µÎ´Â °Í.
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • storage pool disease
    ÀúÀåÁ¶º´
    ÀÀÁýÁ¦, ¿¡Çdz×ÇÁ¸°, ¿ÜÀμº ADP, Æ®·Òºó µî¿¡ ¹ÝÀÀÇÏ¿© ADP¸¦ ¹æÃâÇÏ´Â Ç÷¼ÒÆÇ ±â´É ºÎÀü¿¡ ÀÇÇÑ Ç÷¾× ÀÀ°í Àå¾Ö, °¡º­¿î ÃâÇ÷ Áõ»ó, ÃâÇ÷ ½Ã°£ Áö¿¬, ±³¿øÁúÀ̳ª Æ®·Òºó¿¡ ´ëÇÑ ÀÀÁý ¹ÝÀÀÀÇ °¨Å𸦠Ư¡À¸·Î ÇÑ´Ù.
  • Class III
    3±Þ
    µ¿ÀǾî=mesiocclusion. ÇϾǰú ÇÏ¾Ç Ä¡¾Æ°¡ »ó¾Ç¿¡ ºñÇØ Àü¹æ¿¡ À§Ä¡ÇÑ °æ¿ì.
  • class III malocclusion
    Á¦ III±Þ ºÎÁ¤±³ÇÕ
  • laminar III
    Á¦ 3Ãþ
  • lues III
    ¸Åµ¶ 3±â
    1. Èı⠸ŵ¶Àº ¸Å¿ì µå¹°´Ù. 2. ½É¸Æ°ü°è º´º¯ÀÌ 80¡­85%, ÁßÃ߽Űæ°è º´º¯ 5¡­10%, ³ª¸ÓÁö´Â °£À̳ª ´Ù¸¥ ºÎÀ§¿¡ °í¹«Á¾ÀÌ ¹ß»ýÇÑ´Ù.
  • platelet fector III
    Ç÷¼ÒÆÇ Á¦ »ï ÀÎÀÚ
  • pseudo class III
    °¡¼º III ±Þ
  • pseudotumour :

    pseudounipolar bipolar III disorder

    °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III Àå¾Ö, °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III º´
  • transverse facial fracture : µ¿ÀǾî=Le Forte III fracture.

    transverse facial vein

    °¡·Î ¾ó±¼ µ¿¸Æ
  • true class III
    Áø¼º III±Þ ºÎÁ¤ ±³ÇÕ
  • type III
    3Çü
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
brancher glycogen storage disease Type of glycogen storage disease, due to deficiency of amylo-1,4-1,6-transglucosidase (brancher enzyme).
Synonym: brancher deficiency glycogenosis, debrancher deficiency.
(05 Mar 2000)
cholesterol ester storage disease A rare benign adult form of inherited lysosomal lipid storage disease that is due to deficiency of acid lipase. It results in an accumulation of neutral lipids, particularly cholesterol esters, within cells (particularly leukocytes, fibroblasts, and liver cells). It is an allelic variant of wolman disease.
(12 Dec 1998)
computer storage devices Devices capable of receiving data, retaining data for an indefinite or finite period of time, and supplying data upon demand.
(12 Dec 1998)
cystine storage disease Lysosomal storage disorders of unknown molecular defect, characterised by widespread deposition of cystine crystals in reticuloendothelial cells.
(12 Dec 1998)
disease, lipid storage A series of disorders due to inborn errors in lipid metabolism resulting in the abnormal accumulation of lipids in the wrong places (Examples include Gaucher, Fabry and Niemann-Pick diseases and metachromatic leukodystrophy).
(12 Dec 1998)
disease, phytanic acid storage A genetic disorder of the fatty acid phytanic acid which accumulates and causes a number of progressive problems including polyneuritis (inflammation of numerous nerves), diminishing vision (due to retinitis pigmentosa), and wobbliness (ataxia) caused by damage to the cerebellar portion of the brain (cerebellar ataxia).(refsum's disease)
(12 Dec 1998)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
information storage and retrieval A branch of computer or library science relating to the storage, locating, searching, and selecting, upon demand, relevant data on a given subject.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Glycogen Storage Disease Type III - »õâ An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups Type IIIa and Type IIIb being the most prevalent.
    Synonyms : Cori Disease, Deficiency, Debrancher, Coris Disease, Debrancher Deficiencies, Deficiencies, Debrancher, Dextrinoses, Limit, Dextrinosis, Limit, Disease, Cori, Disease, Cori's, Disease, Forbes, Limit Dextrinoses
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cold storage
    (¸ÔÀ» °ÍµîÀÇ)ÀïÀå;µ¿°á»óÅÂ;¹¦;¹¦Áö
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
  • core storage
    ÀÚ½É ±â¾ï ÀåÄ¡
  • internal storage
    (Àü»ê)³»ºÎ±â¾ïÀåÄ¡
  • main store (storage)
    ÁÖ±â¾ï ÀåÄ¡
  • mass storage
    ´ë·® ±â¾ï(ÀåÄ¡)
  • pumped storage
    ¾ç¼ö ¹ßÀü ÀåÄ¡(ÀúÀü·Â ¼Òºñ½Ã Àú¼öÁö¿¡ ÆÛ¿Ã¸° ¹°·Î °íÀü·Â ¼Òºñ½Ã¿¡ ¹ßÀü) 
  • storage
    ÀúÀå,º¸°ü,â°í,ÃàÀü
  • storage
    ÀúÀå;º¸°ü;â°í;º¸°ü·á;±â¾ï;º¸°ü·á;(ÄÄÇ»ÅÍ)±â¾ï(ÀåÄ¡,ÀúÀå)
  • storage battery
    ÃàÀüÁö
  • storage cell
    ÃàÀüÁö;±â¾ï ´ÜÀ§
  • storage register
    ±â¾ï ·¹Áö½ºÅÍ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov/medlineplus) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (http://www.nlm.nih.gov/medlineplus) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedicineNet.com ÀÇÇлçÀü ¸ÂÃã °Ë»ö (http://www.medicinenet.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedicineNet.com ÀÇÇлçÀü À¯»ç °Ë»ö (http://www.medicinenet.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (http://www.yahoo.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (http://www.yahoo.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á